FECAL MICROBIOTA TRANSPLANTATION IN CRITICAL CONDITION PATIENTS IN HEMATOLOGICAL PRACTICE

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective method to treat malignancy and some solid tumors which may be accompanied by life-threatening immune and infectious complications refractory to standard immunosuppressive and antibacterial therapy. According to literature data, fecal microbiota transplantation (FMT) may be applied to restore functional activity of microbiota and to overcome antibiotic resistance.
Two clinical cases of FMT in critical ill patients who had developed acute graft-versus-host disease (aGvHD) of intestine after allo-HSCT are presented in the article.
The aim of the study was to assess FMT efficiency and safety in immunocompromised critically ill patients.
Results. Following FMT, a complete regress of aGvHD signs as well as reduction of systemic infectious process were registered, due to probable modulation of the immune response. In one patient, elimination from respiratory ways of carbapenemase-producing Klebsiella pneumoniae positive for NDM- and OXA-48- producing was noted, like as elimination of Pseudomonas aeruginosa synthesizing KRS-type carbapenemase.
Conclusions. FMT may be considered an alternative approach to intestinal aGvHD treatment in critically ill patients after allo-HSCT.

1. Аfanasiev B.V., Zubarovskaya L.S., Moiseev I.S. Allogeneic hematopoietic stem cell transplantation in children: current situation, problems, perspectives. Rossiyskiy Journal Detskoy Gematologii i Onkologii, 2015, vol. 2, no. 2, pp. 28-42. (In Russ.)

2. Goloshchapov O.V., Vavilov V.N., Zubarovskaya L.S. et al. Fecal calprotectin is a new quantitative biomarker of the acute and chronic graft-versus-host disease of the gut after allogeneic hematopoietic stem cell transplantation. Klinicheskaya Onkogematologiya, 2011, no. 4 (1), pp. 3-7. (In Russ.)

3. Goloshchapov O.V., Kucher M.А., Suvorova M.А. et al. The first experience of management of multiple resistant infectious complications associated with Clostridium difficile and Klebsiella pneumoniae by fecal microbiota transplantation in the patients after allogeneic hematopoietic stem cell transplantation. Infektsionnye Bolezni, 2017, vol. 3, no. 15, pp. 65-74. (In Russ.)

4. Baxter M., Ahmad T., Colville A. et al. Fatal aspiration pneumonia as a complication of fecal microbiota. Transplant Clin. Infect. Diseases, 2015, vol. 61, no. 1, pp. 136-137.

5. Chiusolo P., Metafuni E., Giammarco S. et al. Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation. Blood, 2012, vol. 120, pp. 4443‒4444. doi: https://doi.org/10.1182/blood-2012-08-447326.

6. Haak B.W., Littmann E.R., Chaubard J.L. Impact of gut colonization with butyrate producing microbiota on respiratory viral infection following allo-HCT. Blood, 2018, vol. 131, no. 26, pp. 2978‒2986.

7. Haak B.W., Prescott H.C., Wiersinga W.J. Therapeutic potential of the gut microbiota in the prevention and treatment of sepsis. Front Immunol., 2018, vol. 9, pp. 2042,

8. Kakihana K., Fujioka Y., Suda W. et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood, 2016, vol. 128, pp. 2083‒2088.

9. Lee J.H., Lim G.Y. Gastrointestinal complications following hematopoietic stem cell transplantation in children. Korean J. Radiol., 2008, vol. 9, no. 5, pp. 449-457.

10. Li Q., Wang C., Tang C. et al. Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. Critical Care, 2015, Feb., pp. 19‒37. doi 10.1186/s13054-015-0738-7.

11. Mahieu R., Cassisa V., Godefroy A. et al. Effect of faecal microbiota transplantation on mouse gut colonization with carbapenemase-producing Escherichia coli. J. Antimicrob. Chemother., 2017, vol. 72, no. 4, pp. 1260–1262. doi: 10.1093/jac/dkw540.

12. Manges A.R., Steiner T.S., Wright A.J. Fecal microbiota transplantation for the intestinal decolonization of extensively antimicrobial-resistant opportunistic pathogens: a review. Infec. Diseases, 2016, vol. 48, no. 8, pp. 587-592.

13. Russell G., Kaplan J., Ferraro M. et al. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics, 2010, vol. 126, no. 1, pp. e239‒е242. doi: 10.1542/peds.2009-3363.

14. Smith P.M., Howitt M.R., Panikov N. et al. The microbial metabolites, short chain fatty acids, regulate colonic Treg cell homeostasis. Science, 2013, vol. 341, pp. 6145,

15. Solari P.R., Fairchild P.G., Noa L.J. et al. Tempered enthusiasm for fecal transplant. Clin. Infect. Diseases, 2014, vol. 59, no. 2, pp. 319.

16. Spindelboeck W., Schulz E., Uhl B. et al. Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host-disease. Haematologica, 2017, May, vol. 102, no. 5, pp. e210-e213.

17. Staffas A., Burgos da Silva M., van den Brink M.R.M. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood, 2017, vol. 129, no. 8, pp. 927-933.

18. Tabbara I.А., Zimmerman K., Morgan C. et al. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch. Intern. Med., 2002, vol. 162, no. 14, pp. 1558‒1566.

19. Swimm A.I., Giver C.R., DeFilipp Z. et al. Indoles derived from intestinal microbiota act via type I interferon signaling to limit Graft-versus-Host-Disease. Blood, 2018, vol. 132, no. 23. doi: 10.1182/blood-2018-03-838193.

20. Wei Y., Yang J., Wang J. et al. Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis. Crit. Care, 2016, vol. 20, no. 332. doi. org/10.1186/s13054-016-1491-2.

21. Zander A.R. Stem cell transplantation for myeloproliferative diseases in the era of molecular therapy. Cellular Therapy and Transplantation (CTT), 2017, vol. 6, no. 4. doi: 10.18620/ctt-1866-8836-2017-6-4-21-27.